<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055258</url>
  </required_header>
  <id_info>
    <org_study_id>KVD824-201</org_study_id>
    <nct_id>NCT05055258</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II</brief_title>
  <acronym>KVD824-201</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of 3 Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatment of Hereditary Angioedema Type I or II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KalVista Pharmaceuticals, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KalVista Pharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess whether different doses of KVD824 are effective in preventing attacks of&#xD;
      Hereditary Angiodedema Type I or Type II.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Rate of Investigator-confirmed HAE attacks during the Treatment Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>To examine the number of investigator-confirmed attacks whilst on treatment compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects without Investigator-confirmed HAE attacks during the Treatment Period.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Investigator-confirmed HAE attacks that require conventional treatment during the Treatment Period.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angioedema Quality of Life Questionnaire (AE-QoL) total score and domain scores during the Treatment Period.</measure>
    <time_frame>12 weeks</time_frame>
    <description>AE-QoL is a quality of life questionnaire with a range of 0 (minimum) to 100 (maximum). A total score of 100 indicates worst possible impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angioedema Control Test (AECT) score and domain scores during the Treatment Period.</measure>
    <time_frame>12 weeks</time_frame>
    <description>AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an AECT score ≥12 at the end of the Treatment Period.</measure>
    <time_frame>12 weeks</time_frame>
    <description>AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Angioedema, Hereditary, Types I and II</condition>
  <arm_group>
    <arm_group_label>300 mg KVD824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg KVD824 twice a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg KVD824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 300 mg KVD824 tablets twice a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>900 mg KVD824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three 300 mg KVD824 tablets twice a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to KVD824</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One, two or three placebo tablets to be taken twice a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KVD824</intervention_name>
    <description>KVD824 300 mg Modified-Release Tablets</description>
    <arm_group_label>300 mg KVD824</arm_group_label>
    <arm_group_label>600 mg KVD824</arm_group_label>
    <arm_group_label>900 mg KVD824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to KVD824</intervention_name>
    <description>Placebo to KVD824 300 mg Modified-Release Tablets</description>
    <arm_group_label>Placebo to KVD824</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects 18 years of age and older.&#xD;
&#xD;
          2. Confirmed diagnosis of HAE type I or II at any time in the medical history:&#xD;
&#xD;
               1. Documented clinical history consistent with HAE (subcutaneous or mucosal,&#xD;
                  nonpruritic swelling episodes without accompanying urticaria) AND EITHER&#xD;
&#xD;
               2. Diagnostic testing results obtained during the Screening Period that confirm HAE&#xD;
                  Type I or II: C1-INH functional level &lt;40% of the normal level. Subjects with&#xD;
                  functional C1-INH level 40-50% of the normal level may be enrolled if they also&#xD;
                  have a C4 level below the normal range. Subjects may be retested during the&#xD;
                  Screening Period if results are incongruent with clinical history or believed by&#xD;
                  the Investigator to be confounded by recent prophylactic or therapeutic C1 INH&#xD;
                  use, OR&#xD;
&#xD;
               3. Documented genetic results that confirm known mutations for HAE Type I or II.&#xD;
&#xD;
          3. Subject has access to and ability to use conventional treatment for HAE attacks.&#xD;
&#xD;
          4. Subject is willing to cease any current medications being taken for HAE prophylaxis&#xD;
             and Investigator determines that doing so would not place the subject at any undue&#xD;
             safety risk.&#xD;
&#xD;
          5. Subject's last dose of attenuated androgens was at least 28 days prior to&#xD;
             randomization.&#xD;
&#xD;
          6. During the Run-in Period subject meets one of the following criteria:&#xD;
&#xD;
               1. Two Investigator-confirmed attacks in the first 4-week period.&#xD;
&#xD;
               2. Three Investigator-confirmed attacks in ≤8 weeks.&#xD;
&#xD;
          7. Subjects who are fertile and heterosexually active must adhere to contraception&#xD;
             requirements throughout the trial as follows:&#xD;
&#xD;
             a) Female subjects must agree to use at least one highly effective contraception&#xD;
             method from the Screening Visit until the end of the trial. Highly effective methods&#xD;
             of contraception include: i) Progestogen-only hormonal contraception associated with&#xD;
             inhibition of ovulation: oral/injectable/implantable (hormonal contraception that&#xD;
             contains estrogen including ethinylestradiol is excluded per Exclusion 4).&#xD;
&#xD;
             ii) Intrauterine device (IUD). iii) Intrauterine hormone-releasing system (IUS). iv)&#xD;
             Bilateral tubal occlusion. v) Vasectomized partner (provided that the partner is the&#xD;
             sole sexual partner of the female subject of childbearing potential and that the&#xD;
             vasectomized partner has received medical assessment of surgical success).&#xD;
&#xD;
             b) Male subjects with a female partner of childbearing potential must agree to use&#xD;
             condoms for the entire Treatment Period AND for 90 days following the final dose of&#xD;
             investigational medicinal product (IMP). Female partners are encouraged to use&#xD;
             contraception as outlined in Inclusion 7a) from the Screening Visit until the end of&#xD;
             the trial. Hormonal contraception that contains estrogen including ethinylestradiol is&#xD;
             acceptable for the female partner.&#xD;
&#xD;
          8. Subjects who are not fertile or not sexually active, as defined below, do not require&#xD;
             contraception.&#xD;
&#xD;
               1. Subjects who refrain from heterosexual intercourse during the trial if the&#xD;
                  reliability of the heterosexual abstinence has been evaluated in relation to the&#xD;
                  duration of the clinical trial and is the preferred and usual lifestyle of the&#xD;
                  subject.&#xD;
&#xD;
               2. Male subjects who are surgically sterile (e.g. vasectomized with medical&#xD;
                  assessment of surgical success).&#xD;
&#xD;
               3. Female subjects who are surgically sterile (e.g. status post hysterectomy,&#xD;
                  bilateral oophorectomy, or bilateral tubal ligation) or post menopausal for at&#xD;
                  least 12 months.&#xD;
&#xD;
          9. Subjects must be able to swallow trial tablets whole.&#xD;
&#xD;
         10. Subjects assessed by the Investigator must be able to appropriately receive and store&#xD;
             IMP, and be able to read, understand, and complete the eDiary.&#xD;
&#xD;
         11. Investigator believes that the subject is willing and able to adhere to all protocol&#xD;
             requirements.&#xD;
&#xD;
         12. Subject provides signed informed consent and is willing and capable of complying with&#xD;
             trial requirements and procedures.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1&#xD;
             inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III),&#xD;
             idiopathic angioedema, or angioedema associated with urticaria.&#xD;
&#xD;
          2. A clinically significant history of poor response to C1-INH therapy or plasma&#xD;
             kallikrein inhibitor therapy for the management of HAE, in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          3. Use of angiotensin converting enzyme (ACE) inhibitors after the Screening Visit or&#xD;
             within 7 days prior to randomization.&#xD;
&#xD;
          4. Any estrogen containing medications with systemic absorption (such as oral&#xD;
             contraceptives including ethinylestradiol or hormonal replacement therapy) after the&#xD;
             Screening Visit or within 7 days prior to randomization.&#xD;
&#xD;
          5. Use of narrow therapeutic index drugs metabolized by CYP3A4 or CYP2C9 or transported&#xD;
             by OAT1, OCT2, and OATP1B1, starting at screening, as determined by the Investigator.&#xD;
&#xD;
          6. Use of strong CYP3A4 inhibitors and inducers during participation in the trial,&#xD;
             starting at the Screening Visit.&#xD;
&#xD;
             Note: These medications include but are not limited to the following:&#xD;
&#xD;
             Inhibitors: boceprevir, clarithromycin, cobicistat, dasabuvir, denoprevir,&#xD;
             elvitegravir, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir,&#xD;
             nefazodone, nelfinavir ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir,&#xD;
             telaprevir, telithromycin, tipranavir, troleandomycin, and voriconazole.&#xD;
&#xD;
             Inducers: apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St.&#xD;
             John's Wort.&#xD;
&#xD;
          7. Inadequate organ function, including but not limited to;&#xD;
&#xD;
               1. Alanine aminotransferase (ALT) &gt; 2x Upper limit of Normal (ULN).&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) &gt; 2x ULN.&#xD;
&#xD;
               3. Bilirubin direct &gt; 1.25x ULN.&#xD;
&#xD;
               4. International normalized ratio (INR) &gt; 1.2.&#xD;
&#xD;
               5. Clinically significant hepatic impairment defined as a Child-Pugh B or C.&#xD;
&#xD;
               6. Estimated glomerular filtration rate (eGFR) &lt;60 mL/min.&#xD;
&#xD;
          8. Any clinically significant comorbidity or systemic dysfunction that in the opinion of&#xD;
             the Investigator would jeopardize the safety of the subject by participating in the&#xD;
             trial.&#xD;
&#xD;
          9. History of substance abuse or dependence that would interfere with the completion of&#xD;
             the trial, as determined by the Investigator.&#xD;
&#xD;
         10. Known hypersensitivity to KVD824 or placebo or to any of the excipients.&#xD;
&#xD;
         11. Any prior use of any gene therapy treatment for HAE.&#xD;
&#xD;
         12. Participation in any interventional investigational clinical trial, including an&#xD;
             investigational COVID-19 vaccine trial, within 4 weeks of the last dosing of&#xD;
             investigational drug prior to screening.&#xD;
&#xD;
         13. Any pregnant or breastfeeding subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>KalVista Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KalVista Pharmaceuticals</last_name>
    <phone>1 (857) 999-0075</phone>
    <email>clinicalstudies@kalvista.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Frankfurt am main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KalVista Investigative Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KVD824</keyword>
  <keyword>KOMPLETE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
    <mesh_term>Hereditary Angioedema Types I and II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

